SureTrader SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

KTOV RSS Feed
Add KTOV Price Alert      Hide Sticky   Hide Intro
Moderator: Millstone, BostonBull1990, whan7
Search This Board:
Last Post: 1/18/2017 10:40:57 AM - Followers: 137 - Board type: Free - Posts Today: 7

\

 

US Office

1615 Suter’s Lane NW, Washington DC 20007, Tel:  +1-202-965-2215

Israel Office

One Azrieli Center, Round Tower, Tel Aviv 6701101



http://kitovpharma.com/

NQ : $KTOV





Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs
that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Kitov is developing combination drug products that treat the pain of osteoarthritis without causing cardiovascular problems.
These drugs will not only not need to be labeled with health warnings, but will actually be labeled as reducing the risk of
cardiovascular events. Kitov’s drugs have the potential to improve the health of millions of patients worldwide.
It is expected that physicians will prefer to prescribe them rather than prescribe two separate drugs, to improve their patients’ health and to reduce their own legal exposure.

Kitov is currently focusing two late-stage drugs. Both contain NSAIDs that are widely consumed throughout the world for treating osteoarthritis.
Each of Kitov’s drugs adds to the NSAID a second drug product that reduces hypertension.

KIT-301: Naproxen combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled
for 20-24 months from start of development.
KIT-302: Celecoxib combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled for 2015.

Osteoarthritis, affecting approximately half of all adults over the age of 50, is a degenerative disease of joints that can cause pain and limit mobility.
Exercise and weight control are important therapies for controlling symptoms, but for many patients medication is the next step in pain treatment.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for treating osteoarthritis pain.
However, these medications raise blood pressure (hypertension) and thereby increase the risk of heart attacks, strokes, and death.
This has led the US FDA to require including a black box warning in the labeling of all NSAIDs, warning of these increased cardiovascular risks.




 

Dr. John Paul Waymack – M.D., Sc.D.

Chairman of the Board of Directors and Chief Medical Officer

Dr. Waymack was one of the founders of Kitov Pharmaceuticals and has served as the Chairman of our Board of Directors and Chief Medical Officer since July 2013. Dr. Waymack has over 20 years of experience in the biopharma field. Dr. Waymack is a former academic transplant surgeon and a former FDA medical officer, with over fifteen years of experience in drug development as a consultant to major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10 years of academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and immunology. In addition, Dr. Waymack volunteered to the U.S. army, where he was commissioned and served as a Major in the Medical Corp. in the position of Chief of Surgical Research in the U.S. Army’s Institute for Surgical Research. Dr. Waymack was also an associate professor of surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey.






 

NEWS :

Dec. 17, 2015 :  Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302
http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-reports-additional-data-from-its-phase-iii-trial-on-the-beneficial-blood-pressure-effects-of-kit-302-300194664.html


November 20, 2015 : Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-holdings-announces-pricing-of-us-initial-public-offering-and-nasdaq-listing-552301701.html


October 21, 2015 : Kitov Pharma Announces Completion of Patient Recruitment for the Phase III Clinical Trial for KIT-302
http://www.prnewswire.com/news-releases/kitov-pharma-announces-completion-of-patient-recruitment-for-the-phase-iii-clinical-trial-for-kit-302-535035241.html








 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KTOV
Current Price
Volume:
Bid Ask Day's Range
SureTrader
KTOV News: Report of Foreign Issuer (6-k) 01/17/2017 03:24:26 PM
KTOV News: Report of Foreign Issuer (6-k) 01/13/2017 08:40:01 AM
KTOV News: Report of Foreign Issuer (6-k) 01/12/2017 02:31:38 PM
KTOV News: Notice of Effectiveness (effect) 12/14/2016 06:01:56 AM
KTOV News: Notice of Effectiveness (effect) 12/14/2016 06:01:55 AM
PostSubject
#5198   That would be a nice scenario to have happen!!! tmeier 01/18/17 10:40:56 AM
#5197   Very interesting! scottsmith 01/18/17 10:33:23 AM
#5196   TEVA connection to new acquisition may hold the RBNEWS 01/18/17 10:31:21 AM
#5195   The one thing I keep thinking is how ylama3 01/18/17 09:56:58 AM
#5194   Looks like KTOV is gapping up on yesterdays BEANPOLE 01/18/17 08:20:32 AM
#5193   Nice action in TASE: midastouch017 01/18/17 08:05:16 AM
#5192   I am hoping NDA/license deal news after market tjguy 01/18/17 06:57:57 AM
#5191   I am hoping NDA/license deal news after LearnToTrade 01/17/17 11:24:32 PM
#5190   Agree. That's the heart of my post. RBNEWS 01/17/17 08:19:54 PM
#5189   Was pleased to see the company respond to scottsmith 01/17/17 08:13:51 PM
#5188   Just Need a couple of very possible items RBNEWS 01/17/17 06:20:36 PM
#5187   True! Fingers crossed! midastouch017 01/17/17 03:54:05 PM
#5186   Market definitely liked this news! MDizzle 01/17/17 03:52:36 PM
#5185   Kitov to Host Business Update Call on Monday, midastouch017 01/17/17 02:40:39 PM
#5184   Yeah, so i noticed! midastouch017 01/17/17 02:28:09 PM
#5183   But unfortunately, the price continues to fall :( DrStockonomics 01/17/17 12:39:29 PM
#5182   FWIW Shares of Kitov Pharmaceuticals Holdings Ltd. (NASDAQ:KTOV) have midastouch017 01/17/17 06:54:16 AM
#5181   I'd be very happy with 1M KTOV :-) mdimport 01/16/17 03:27:37 PM
#5180   Use Google Translate. Put the language in one mdimport 01/16/17 03:24:47 PM
#5179   Or the 10 KTOV shareholders on IH who pgh_maulers 01/16/17 03:23:15 PM
#5178   In my opinion, KTOV Management is doing fine. mdimport 01/16/17 03:19:59 PM
#5177   Hope u r right. pgh_maulers 01/16/17 03:09:30 PM
#5176   I agreed that they delayed one time. Originally LearnToTrade 01/16/17 02:59:31 PM
#5175   I thought they were initially saying they would pgh_maulers 01/16/17 02:55:13 PM
#5174   It went down last Friday because everyone disappointed LearnToTrade 01/16/17 02:53:57 PM
#5173   There's no multiple delay. I don't know LearnToTrade 01/16/17 02:44:57 PM
#5172   Why did this drop so much on Friday. pgh_maulers 01/16/17 02:05:13 PM
#5171   Because the low share structure, a license deal LearnToTrade 01/16/17 08:58:29 AM
#5170   Total ads shares I guess we got around LearnToTrade 01/16/17 08:42:18 AM
#5169   21 million shares x 0.6NIS=12.6 million NIS midastouch017 01/16/17 08:41:34 AM
#5168   If I added right, ktov bought Tyrnovo for LearnToTrade 01/16/17 08:32:45 AM
#5167   21,000,000 ????? ???????? ????? ????? ????? TYRNOVO. midastouch017 01/16/17 08:05:57 AM
#5166   Ktov probably buy the other 44% by 21m LearnToTrade 01/16/17 08:01:57 AM
#5165   Need someone to translate Hebrew. LearnToTrade 01/16/17 07:54:45 AM
#5164   TASE news out: CEO Stock Exchange for LearnToTrade 01/16/17 07:53:01 AM
#5163   Great DD. Would be nice if ktov scottsmith 01/15/17 06:04:37 PM
#5162   In general. I think it's almost the perfect RBNEWS 01/15/17 03:16:11 PM
#5161   From last SEC filing EnricoMania 01/15/17 02:46:46 PM
#5160   The market for immuno-oncology treatments is believed to tjguy 01/15/17 03:20:21 AM
#5159   Wondering why No mention of NT157 in PR? djpope 01/14/17 05:38:41 PM
#5158   >Inhibition of IGF-1 signaling promotes proteostasis djpope 01/14/17 05:33:31 PM
#5157   Nice DD and nice find!! Backdraft4u 01/14/17 02:56:16 PM
#5156   Nice find! One more Teva connection for Kitov... scottsmith 01/14/17 10:46:49 AM
#5155   Found this EnricoMania 01/14/17 08:31:36 AM
#5154   NDA is still coming anytime now. But, given RBNEWS 01/13/17 05:02:04 PM
#5153   Does anybody have any thoughts or ideas where LittleBytor 01/13/17 04:59:48 PM
#5152   Wow, and I thought I finally got myself LittleBytor 01/13/17 04:40:41 PM
#5151   Yes. Burn your computer so you don't scottsmith 01/13/17 04:25:58 PM
#5150   I think people don't understand why company want DavidW2 01/13/17 04:11:07 PM
#5149   So pretty much everything we have been waiting LittleBytor 01/13/17 01:56:10 PM
PostSubject